JanOne Inc. Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Tables)

6 Months Ended

Jul. 01, 2023

Intangible assets as of July 1, 2023 and December 31, 2022 consist of the following (in $000’s):


	July 1, 2023		December 31, 2022
Patent and domains	$	4	$	4
Soin intangibles *	$	19,293	$	19,293
Computer software	—		3,563
Intangible assets from discontinued operations	—		735
Intangible assets	19,297		23,595
Less accumulated amortization	(726)		(3,563)
Total intangible assets	$	18,571	$	20,032

*The Soin intangibles acquired by the Company consist of the following:

1.Three pending patents related to the methods of using low-dose Naltrexone to treat chronic pain;

2.Final formula for Naltrexone; and

3.Orphan drug designation as approved by the FDA.